Yes—these drugs raised Hemoglobin by an average of 0.60 g/dL compared with other treatments or a dummy pill. Researchers combined 85 studies involving 70,543 people. They looked at SGLT2 Inhibitors, medicines such as empagliflozin that help remove sugar through urine. People in the studies had diabetes, heart disease, heart failure, or long-term kidney disease. Each study assigned treatments by chance. Comparison groups received a dummy pill or another blood sugar medicine. The review found small but consistent increases in two blood measures. Hemoglobin is the protein that carries oxygen in blood. Its average rise was 0.60 g/dL above the comparison groups. Hematocrit, the share of blood made up of red cells, rose by 2.36%. The middle follow-up length across the studies was 24 weeks. The findings suggest these medicines may affect how the body handles iron. They may also affect how it makes red cells. But higher blood counts do not yet explain the drugs’ benefits. Researchers still do not know whether these changes directly help protect the heart or kidneys. For BioSocial members, this adds context to bloodwork tracked alongside medication use. A record of results before and after starting can help show your own pattern. The study averages are not targets for your results. Sharing test dates and time on treatment can make community comparisons more useful. It also leaves room for people whose numbers stayed steady. What changes, if any, have you seen in your blood counts since starting these medicines?